pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ROCHE · news · pharmadog
← back to ROCHE
News mentioning ROCHE
261
stories
20d
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
biospace
21d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
21d
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
21d
GSK lays off 650 staffers amid closure of German vaccine manufacturing site
biospace
21d
AstraZeneca’s newly approved pill fails frontline breast cancer study
biopharma dive
22d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
22d
Scholar Rock SMA drug approved by FDA
biopharma dive
22d
Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
fiercebiotech
22d
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
22d
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
25d
Frazier adds $1.1B+ to small and mid-sized biotech fund
biospace
25d
FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer
fiercebiotech
25d
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
26d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
26d
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
27d
Beeline flies into phase 3 as oral lupus drug soars past placebo
fiercebiotech
27d
Beyond China: Five other overseas destinations for biopharma dollars
biospace
28d
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
fiercebiotech
28d
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
fiercebiotech
28d
Reeling from past failures, Parkinson's pipeline enters 'era of diversification'
biospace
Sep 4, 26
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
Sep 3, 26
GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
fiercebiotech
Sep 2, 26
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
biopharma dive
Sep 2, 26
STAT+: ARPA-H funds biotechs working on custom RNA therapies
stat
Sep 2, 26
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
biospace
Sep 2, 26
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
biospace
Sep 1, 26
Novartis says MS pill succeeds in two large studies
biopharma dive
Sep 1, 26
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
biospace
Sep 1, 26
Roche taps Simcere for trispecific T cell engager pact with $75M upfront
endpoints
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
← prev
page 4 of 9
next →
